Allergan anti-infective drug gets FDA expansion approval

Allergan plc says the FDA has approved a label expansion of its anti-infective drug, Avycaz, in pediatric patients. The drug is now approved as monotherapy for complicated urinary tract infections (cUTI), and in combination with metronidazole for complicated intra-abdominal infections (cIAI).

This is the first drug to receive approval for pediatric patients with cUTI or cIAI in more than a decade. The drug is already approved in adult patients with similar indications.So far this year, Allergan’s shares have outperformed the industry. The stock has rallied 12.8% in the period, compared with the strong performance for the industry.

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.